NZ614081B2 - Auto-injector - Google Patents
Auto-injector Download PDFInfo
- Publication number
- NZ614081B2 NZ614081B2 NZ614081A NZ61408112A NZ614081B2 NZ 614081 B2 NZ614081 B2 NZ 614081B2 NZ 614081 A NZ614081 A NZ 614081A NZ 61408112 A NZ61408112 A NZ 61408112A NZ 614081 B2 NZ614081 B2 NZ 614081B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- carrier
- chassis
- case
- needle
- spring
- Prior art date
Links
- 229940090047 Auto-Injector Drugs 0.000 title claims abstract description 76
- 239000000969 carrier Substances 0.000 claims abstract description 306
- 239000007924 injection Substances 0.000 claims abstract description 85
- 238000002347 injection Methods 0.000 claims abstract description 84
- 239000003814 drug Substances 0.000 claims abstract description 39
- 230000001808 coupling Effects 0.000 claims abstract description 25
- 238000010168 coupling process Methods 0.000 claims abstract description 25
- 238000005859 coupling reaction Methods 0.000 claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 150000002500 ions Chemical class 0.000 claims description 31
- 230000037250 Clearance Effects 0.000 claims description 6
- 230000035512 clearance Effects 0.000 claims description 6
- 238000009877 rendering Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 50
- 101700024131 EXE4 Proteins 0.000 description 34
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 34
- 229960001519 exenatide Drugs 0.000 description 34
- 102000004877 Insulin Human genes 0.000 description 24
- 108090001061 Insulin Proteins 0.000 description 24
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 19
- 210000003491 Skin Anatomy 0.000 description 17
- 230000001681 protective Effects 0.000 description 14
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 230000001960 triggered Effects 0.000 description 9
- 229940035295 Ting Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940079593 drugs Drugs 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 206010012601 Diabetes mellitus Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Enoxaparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 210000003811 Fingers Anatomy 0.000 description 4
- 102000004965 antibodies Human genes 0.000 description 4
- 108090001123 antibodies Proteins 0.000 description 4
- 238000007906 compression Methods 0.000 description 4
- 230000000994 depressed Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000000979 retarding Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000000881 depressing Effects 0.000 description 2
- 101710038873 glc-1 Proteins 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000004026 insulin derivative Substances 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- -1 relin Chemical compound 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hy Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229960005153 Enoxaparin sodium Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229960002913 Goserelin Drugs 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 210000003016 Hypothalamus Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 229940118179 Lovenox Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 206010027599 Migraine Diseases 0.000 description 1
- 208000008085 Migraine Disorders Diseases 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 208000003385 Rhinitis, Allergic, Seasonal Diseases 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N Terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 210000003813 Thumb Anatomy 0.000 description 1
- 210000003371 Toes Anatomy 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229960004824 Triptorelin Drugs 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic Effects 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- NFLWUMRGJYTJIN-PNIOQBSNSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-PNIOQBSNSA-N 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000003116 impacting Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 230000021037 unidirectional conjugation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
- A61M2005/208—Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
- A61M2005/3247—Means to impede repositioning of protection sleeve from needle covering to needle uncovering position
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31501—Means for blocking or restricting the movement of the rod or piston
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
- A61M5/3158—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod performed by axially moving actuator operated by user, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
- A61M5/3204—Needle cap remover, i.e. devices to dislodge protection cover from needle or needle hub, e.g. deshielding devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3245—Constructional features thereof, e.g. to improve manipulation or functioning
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/50—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile
- A61M5/5086—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for preventing re-use, or for indicating if defective, used, tampered with or unsterile for indicating if defective, used, tampered with or unsterile
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
- F04C2270/00—Control; Monitoring or safety arrangements
- F04C2270/04—Force
- F04C2270/042—Force radial
- F04C2270/0421—Controlled or regulated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T403/00—Joints and connections
- Y10T403/32—Articulated members
- Y10T403/32254—Lockable at fixed position
- Y10T403/32467—Telescoping members
- Y10T403/32475—Telescoping members having detent
- Y10T403/32501—Cam or wedge
Abstract
auto-injector (1) for administering a dose of a liquid medicament (M) is disclosed. After the liquid medicament has been injected the injection needle is automatically retracted. The auto-injector has a tubular chassis (2) telescopable in a tubular case (12) and a carrier subassembly comprising a tubular carrier (7) slidably arranged relative to the chassis (2) inside the case (12). The carrier (7) is adapted to contain a syringe (3) with a hollow injection needle (4), a drive spring (8) and a plunger (9) for forwarding load of the drive spring (8) to a stopper (6) of the syringe (3). The syringe (3) is lockable for joint axial translation with the carrier (7). A trigger button (13) is arranged distally or laterally in or on the case (12). A control spring (19) is arranged around the carrier (7) with a needle extension control mechanism (24) for coupling a proximal end of the control spring (19) to either the carrier (7) for advancing it for needle extension or to the chassis (2) for needle retraction depending on the relative axial position of the carrier (7) and the chassis (2). A plunger release mechanism (27) is arranged for releasing the plunger (9) for injection when the carrier (7) has at least almost reached an extended proximal position. Adetent mechanism (18) is arranged for coupling the chassis (2) to the carrier (7) for joint axial translation relative to the case (12), wherein the detent mechanism (18) decouples the chassis (2) from the carrier (7) upon actuation of the trigger button (13) thus allowing the carrier (7) to move relative to the chassis (2) so as to cause the needle extension control mechanism (24) to switch the proximal end of the control spring (19) to the carrier (7) for needle extension. A syringe retraction control mechanism (25) is arranged for coupling a distal end of the control spring (19) to either the carrier (7) for needle retraction or to the case (12) otherwise. tubular carrier (7) slidably arranged relative to the chassis (2) inside the case (12). The carrier (7) is adapted to contain a syringe (3) with a hollow injection needle (4), a drive spring (8) and a plunger (9) for forwarding load of the drive spring (8) to a stopper (6) of the syringe (3). The syringe (3) is lockable for joint axial translation with the carrier (7). A trigger button (13) is arranged distally or laterally in or on the case (12). A control spring (19) is arranged around the carrier (7) with a needle extension control mechanism (24) for coupling a proximal end of the control spring (19) to either the carrier (7) for advancing it for needle extension or to the chassis (2) for needle retraction depending on the relative axial position of the carrier (7) and the chassis (2). A plunger release mechanism (27) is arranged for releasing the plunger (9) for injection when the carrier (7) has at least almost reached an extended proximal position. Adetent mechanism (18) is arranged for coupling the chassis (2) to the carrier (7) for joint axial translation relative to the case (12), wherein the detent mechanism (18) decouples the chassis (2) from the carrier (7) upon actuation of the trigger button (13) thus allowing the carrier (7) to move relative to the chassis (2) so as to cause the needle extension control mechanism (24) to switch the proximal end of the control spring (19) to the carrier (7) for needle extension. A syringe retraction control mechanism (25) is arranged for coupling a distal end of the control spring (19) to either the carrier (7) for needle retraction or to the case (12) otherwise.
Description
Auto-injector
Technical Field
The invention relates to an auto-injector for administering a dose of a liquid medicament
according to the preamble of claim 1.
Background of the ion
Administering an ion is a process which presents a number of risks and nges
for users and healthcare professionals, both mental and physical.
Injection devices (Le. devices capable of delivering medicaments from a medication
container) typically fali into two categories —— manual devices and njectors.
in a manual device — the user must provide the mechanical energy to drive the fluid
through the . This is typically done by some form of button / plunger that has to
be continuously pressed by the user during the injection. There are numerous
disadvantages to the user from this approach. If the user stops pressing the button /
plunger then the injection will also stop. This means that the user can deliver an
ose if the device is not used properly (Le. the plunger is not fully pressed to its
end on). Injection forces may be too high for the user, in particular if the patient is
elderly or has dexterity problems.
The extension of the button/plunger may be too great. Thus it can be inconvenient for
the user to reach a fully extended button. The combination of injection force and button
extension can cause trembling / shaking of the hand which in turn increases discomfort
as the inserted needle moves.
Auto—injector devices aim to make dministration of injected therapies easier for
patients. Current therapies delivered by means of self-administered injections include
drugs for diabetes (both insulin and newer GLP-1 class drugs), migraine, hormone
therapies, anticoagulants etc.
Auto-injectors are devices which completely or partially replace activities involved in
parenteral drug delivery from standard syringes. These activities may include removal of
a protective syringe cap, insertion of a needle into a patient’s skin, injection of the
medicament, removal of the needle, shielding of the needle and preventing reuse of the
. This overcomes many of the disadvantages of manual devices. injection forces I
button extension, hand-shaking and the likelihood of ring an incomplete dose are
reduced. Triggering may be performed by numerous means. for example a trigger button
or the action of the needle reaching its injection depth. In some devices the energy to
deliver the fluid is provided by a spring.
US 2002/0095iZO A1 discloses an automatic injection device which automatically s
a pre-measured quantity of fluid medicine when a tension spring is released. The tension
spring moves an ampoule and the injection needle from a storage position to a deployed
position when it is released. The content of the ampoule is thereafter expelled by the
tension spring forcing a piston forward inside the e. After the fluid medicine has
been ed, torsion stored in the tension spring is released and the ion needle is
automatically retracted back to its al storage on.
High viscosity ments require high forces for expelling them through the relatively
thin injection needle. To achieve these forces strong drive springs are needed. This can
lead to a high impact felt by the user when inserting the needle into the skin and to high
forces felt by the user when triggering the ion.
Summary of the Invention
3O It is an object of the t invention to provide an improved auto-injector and an
improved method for operating an auto-injector, or to at least provide the public with a
useful choice.
The object is ed by an auto—injector according to claim 1 and by a method
according to claim 13.
Preferred embodiments of the ion are given in the dependent claims.
in the context of this specification the term proximal refers to the direction pointing
s the t during an injection while the term distal refers to the opposite
direction pointing away from the patient. The term s refers to a radial ion
pointing towards a longitudinal axis of the auto-injector whereas the term outwards refers
to the opposite direction iy pointing away from the longitudinal axis.
According to the invention an njector for administering a dose of a liquid
medicament comprises:
- a tubular chassis telescopable in a tubular case,
- a carrier subassembly comprising a tubular carrier slidably arranged relative to
the chassis inside the case, the carrier adapted to contain a syringe with a hollow
injection needle, a drive spring and a plunger for forwarding load of the drive spring to a
stopper of the syringe, wherein the syringe is iockabie nt axial translation with the
carrier,
- a trigger button arranged distally or laterally in or on the case,
- a control spring arranged around the carrier,
- a needle extension control mechanism for coupling a proximal end of the l
spring to either the carrier for advancing it for needie extension or to the chassis for
needle retraction depending on the relative axial position of the carrier and the chassis,
~ a plunger release mechanism arranged for releasing the plunger for expelling the
medicament when the carrier has at least almost reached 3 extended proximal on,
— a detent mechanism arranged for coupling the chassis to the carrier for joint axial
translation relative to the case, wherein the detent ism is arranged to le
the chassis from the carrier upon actuation of the trigger button thus allowing the carrier
to move relative to the chassis so as to cause the needle extension control mechanism to
switch the proximal end of the control spring to the r for needle extension,
~ a syringe retraction l mechanism arranged for coupling a distal end of the
3O control spring to either the carrier for needle retraction or to the case otherwise.
According to the invention, there is also provided a method of operating an auto~injector,
the auto-injector comprising: a tubular chassis teiescopable in a tubular case, a carrier
subassembly comprising a tubular carrier slidably arranged relative to the chassis inside
the case, the carrier adapted to contain a syringe with a hollow injection needle, a drive
spring and a plunger for forwarding load of the drive spring to a r of the syringe.
wherein the syringe is lockable forjoint axial ation with the r, a trigger button
arranged distally or laterally in or on the case, a control spring ed around the
r, a needle extension control mechanism for ng a proximal end of the control
spring to either the carrier or to the chassis, a r release mechanism arranged for
locking the drive spring, a detent mechanism ed for ng the chassis to the
carrier, a syringe retraction control mechanism arranged for coupling a distal end of the
control spring to either the carrier or to the case, the method sing the steps of:
coupling the proximai end of the control spring to the carrier by the needle extension
control mechanism, preventing release of the drive spring by the plunger release
“IO mechanism, preventing decoupling of the chassis from the carrier by the detent
ism and coupling the distal end of the control spring to the case by the syringe
retraction control mechanism in an initial state, translating the case in the proximal
ion relative to the chassis against the force of the control spring unlocking the
detent mechanism when the case is translated into an advanced position thereby
allowing translation of the carrier relative to the chassis translating the carrier in the
proximal direction thereby switching the needle extension control mechanism so as to
decouple the proximal end of the control spring from the chassis and couple it to the
r, thereby releasing the control spring for advancing the carrier for needle
extension, releasing the drive spring by the plunger release mechanism when the needle
at least almost reaches an extended proximal position thereby allowing the drive spring
to advance the plunger and the stopper for at least partially expelling the medicament,
translating the case in the distal ion under load of the control spring relative to the
carrier ling the proximal end of the control spring from the carrier and coupling it
to the chassis by the needle extension control mechanism and decoupling the distal end
of the l spring from the case and coupling it to the carrier by the syringe retraction
control mechanism when the case reaches a defined on relative to the carrier during
translation in the distal direction, retracting the carrier subassembly into the chassis into a
needle safe position under load of the control spring.
3O Comprises/comprising and grammatical variations f when used in this specification
are to be taken to specify the presence of stated features, integers, steps or components
or groups thereof, but do not preclude the presence or addition of one or more other
features, integers, steps, components or groups thereof.
The carrier subassembly with the integrated drive spring allows for employing a strong
drive spring without any impact on the user when triggering the auto—injector or during
needle extension since these actions are achieved or opposed by the control spring
which can be specified considerably weaker than the drive spring. This allows for
delivering highly viscous medicaments.
There are a number of significant benefits of ting the ons between the drive
spring and the control spring in this way. The auto—injector is always needle safe, i.e. the
needle can be retracted before the injection is complete. The reliability of the auto-
injector is improved as the ents for needle advance and retraction are not loaded
by the high impact of a freely expanding high force drive spring. The auto~injector is well
suited to serve as a platform as the drive spring can be swapped to deliver different
viscosity drugs without affecting the ion or retraction functions. This is particularly
advantageous for high viscosity fluids.
Releasing the drive spring upon the needle reaching an advanced proximal position, eg.
when the needle is advanced to a corresponding ion depth, avoids a so called wet
injection, i.e. medicament leaking out of the needle which is a problem in conventional art
auto-injectors, where both needle extension and injection are achieved by pushing on the
r. The njector according to the invention solves the wet injection problem by
the separate springs for translation of the carrier and for drug delivery.
The auto~injector according to the invention has a particularly low part count compared to
most conventional auto-injectors thus reducing manufacturing costs. The arrangement
with te control spring and drive spring for fluid injection allows for using one design
for different viscosity liquids byjust changing the drive spring, and for different volumes
just by changing the length of the plunger. This is an advantage over
conventional art s where the main spring also powers needle extension and/or
retraction.
in the context of this specification the chassis is generally considered as being fixed in
position so motion of other ents is described relative to the s.
in an initial as delivered state of the auto-injector the proximal end of the control spring
is coupled to the chassis by the needle extension control mechanism while the distal
end is coupled to the case by the syringe retraction control mechanism, release of the
drive spring is prevented by the plunger release mechanism, decoupling of the chassis
from the r is prevented by the detent mechanism.
In order to trigger the njector the case has to be translated in the proximal
direction relative to the chassis against the force of the control spring. When the case
has at least almost reached an advanced proximal position the detent mechanism is
unlocked thereby allowing translation of the carrier relative to the chassis. Preferably
this position has been reached, when the case has moved 85%-98% of its total proximal
extension. The relative translation of the case and the chassis could be achieved, eg.
by fixing the chassis and moving the case. For the purpose of injection, e.g., the chassis
may be fixed by ng against an injection site, eg. a t's skin. Hence a user,
eg. the patient or a caregiver, could grab the case with their whole hand and push the
chassis protruding from the proximal end against the injection site, thereby translating
the case relative to the chassis in proximal direction and triggering the auto-injector in a
way described above.
The carrier now is unlocked to be translated in the proximal direction. As the carrier
translates in the proximal direction relative to the case and to the chassis it thereby
switches the needle extension l mechanism depending on the relative position of
the carrier in the chassis so as to decouple the al end of the control spring from
the chassis and couple it to the carrier, thereby releasing the control spring for
advancing the r for needle extension. For the purpose of injection, e.g., the user
could ly depress a r button coupled to the carrier forcing the carrier in the
proximal direction. This would cause the needle to be extended according to the needle
extension control mechanism described before. Again, for purpose of injection, the user
pushing the or against an injection site could press the trigger button thereby
translating the carrier in the proximal ion relative to the case and the chassis
thereby switching the needle extension control mechanism as described before.
Advancing the carrier under the force of the control spring would then result in
advancing the needle into the skin.
Alternatively the control spring could lly be coupled to the carrier by the needle
1O extension control mechanism so that the r would be immediately advanced when
the detent ism is unlocked by translation of the case into the advanced position.
As the needle translates with the r subassembiy to an extended proximal position,
where it is no longer needle safe, the drive spring is released by the plunger release
mechanism thereby allowing the drive spring to advance the plunger and the stopper for
at least partially expelling the ment. This release of the drive spring is preferably
triggered by the carrier reaching a predefined relative position within the case. This
position is reached, when the carrier has at least almost reached the ed proximal
position. Preferably, this position is at 85% to 98% proximal extension. if, for example,
the extension length is ‘1 cm the position would fall into the range of 8,5mm — 9,8mm
proximal extension length
For the e of injection the extended proximal position may correspond to an
intended injection depth. Hence the drive spring could be released by the plunger
release mechanism once the injection depth is substantially d thereby allowing
the drive spring to advance the plunger and the stopper for at least partially delivering
the medicament.
If the auto-injector is removed from the injection site after the stopper has bottomed out
in the syringe or at any point during injection, the case is translated in the distal direction
3O under load of the l spring relative to the carrier subassembiy.
The needle retraction is triggered by moving the case in distal direction relative to the
chassis and the carrier under the force of the control spring. As the case s a
defined position relative to the carrier the proximal end of the control spring is
decoupled from the carrier and d to the s by the needle extension control
mechanism. Furthermore the distal end of the control spring is decoupled from the
r sleeve and coupled to the carrier by the syringe retraction control mechanism.
The sequencing of this switching is critical as tion will fail if both collars are
attached to the carrier at the same time. This is overcome by separating the switching of
the collars by a significant displacement of the case, which es for first switching
the needle extension control mechanism and then the syringe tion control
mechanism, e.g.
As the control spring now pushes against the chassis in the proximal direction and
against the carrier in the distal direction the r subassembly is retracted into the
chassis into a needle safe position by the control spring, where the proximai end of the
needle is covered. As this retraction is triggered by the relative position between case,
chassis, and carrier, it is particularly independent from ing the medicament. For
the purpose of injection this position of the case relative to the carrier could be reached,
eg. if the auto-injector is removed from the injection site. When,e.g., the user still
grabbing the case with their whole hand and g the chassis protruding from the
proximal end against the injection site move their hand in distal direction, the case will
be moved in distal direction relative to the carrier and the chassis and the mechanism
will be triggered as described before. The needle will thus be retracted from the injection
site under the force of the control spring.
ing to one embodiment the needle extension control ism may comprise a
first collar biased by the control spring in the proximal direction, wherein at ieast one
resilient beam is proximally arranged on the first collar, wherein respective recesses are
arranged in the carrier and case, wherein a transversal extension of a head of the
resilient beam is wider than a gap n the carrier and the chassis causing the head
of the resilient beam to abut a distal face on the recess in the chassis while being
ted from deflecting in an inward direction by the carrier or to abut a distal face on
the recess in the r while being prevented from deflecting in an outward direction by
the chassis thereby ding load from the control spring to the carrier for needle
extension, wherein the resilient beam is ed to be switched between the chassis
and the carrier by ramped engagement of the head to the distal faces under load of the
control spring ing on the relative longitudinal position between the chassis and
the carrier. As the head of the resilient beam may be inwardly and outwardly ramped it
may be referred to as an arrowhead.
The plunger release mechanism may comprise at least one resilient arm on the carrier
1O arranged to be in a ramped engagement to the plunger so as to disengage them under
load of the drive spring, n a peg protrudes from a distal end face of the trigger
button in the proximal direction in a manner to support the resilient arm ting
disengagement of the carrier from the plunger and thus e of the drive spring when
the r is in a distal on. The trigger button is arranged to remain in position
relative to the case when the carrier is translated for advancing the needle. That means,
the trigger button, initially coupled to the carrier, pushes the carrier in the proximal
direction when sed. As soon as the control spring takes over further ing
the carrier the trigger button may abut the case and decouple from the carrier, staying in
position as the carrier moves on. Hence the resilient arm is pulled away from the peg
thus ailowing tion otthe resilient arm due to the ramped engagement under load
of the drive spring for disengaging the plunger from the carrier and releasing the drive
spring for drug delivery when the carrier has reached a predefined position during
needle advancement.
The detent ism may be arranged to provide a resistive force which has to be
overcome to advance the carrier in the proximal direction for needle extension. The
carrier may be coupled to a trigger button and the force pushing the trigger button has
to exceed the resistive force of the detent mechanism. E.g., once the user applies a
force on the trigger button which exceeds a pre—determined value the detent mechanism
releases, initiating the injection cycle. if the pre—determined value is not overcome the
detent mechanism pushes the carrier and trigger button back into their prior position.
This ensures that the auto-injector is always in a defined state, either triggered or not
triggered, not half triggered by the user hesitating.
The detent ism may also be ed to provide a resistive force resisting
translation of the carrier in the distal direction ve to the chassis for keeping the
carrier in a defined position in a transitional state with both ends of the control spring
decoupled from the carrier. This transitional state may be required for retracting the
needle on removal from the injection site. As the carrier is biased against the injection
site by the control spring before removal from the injection site it has to be led
from the al end ofthe l spring and coupled to the distal end for retraction.
The sequencing of this ing is critical as tion will fail if both ends of the
control spring are attached to the carrier at the same time. This is overcome by
separating the switching of the ends by a significant displacement of the case, which
moves in the distal direction ve to the chassis on removal of the injection site under
’15 load of the control spring. As the switching of the distal end of the control spring to the
carrier depends on the relative position of the case to the carrier the carrier has to be
fixed in the transitional state which is achieved by the detent mechanism.
In one embodiment the detent mechanism comprises a resilient beam on the chassis
and a rhomboid ramp member on the carrier, the resilient beam being essentially
straight when d and having a first beam head arranged to interact in a ramped
engagement with a proximal fourth ramp or a distal fifth ramp on the rhomboid ramp
member in such a manner that application of a translative force on the carrier relative to
the chassis in the al direction with the first beam head engaged to the fourth
ramp deflects the resilient beam in one transversal direction, e.g. outwards when a
predetermined value of the translative force, at least ing on the resilience of the
resiiient beam, is overcome so as to allow the first beam head to travel along one
transversal side of the rhomboid ramp member on continued relative translation of the
components. The beam head may protrude transversally from the resilient beam in a
mannerto distort the resilient beam by lever action when pushed against the rhomboid
ramp memberthereby also defining the predetermined value of the translative force to
be overcome by the carrier. Furthermore, the contacting faces of the first beam head
and the rhomboid ramp member may have their friction adapted to define the required
force by appropriately choosing their shape and material properties. The resilient beam
is d to relax when the first beam head has reached the fifth ramp thereby
engaging it in a manner that application of a translative force on the carrier in the distal
direction deflects the resilient beam in the other transversal direction, e.g. inwards when
a predetermined value of the translative force, at least depending on the resilience of
the ent beam, is overcome so as to allow the first beam head to travel along the
other transversal side of the rhomboid ramp member on continued ation of the
carrier. The first beam head may also be allowed to relax behind the fourth ramp at the
end of this motion for preventing the carrier from being advanced again, e.g. when the
auto-injector is being heavily shaken after use.
it goes without saying that the positions of the ent beam on the s and the
rhomboid ramp member on the carrier may be switched without altering the function of
the detent mechanism.
When the auto-injector or the syringe is assembled a protective needle sheath may be
ed to the needle for keeping the needle sterile and preventing both, damage to
the needle during assembly and handling and access of a user to the needle for
avoiding finger stick es. l of the protective needle sheath prior to an
injection usually requires a vely high force for pulling the protective needle sheath
off the needle and needle hub in the proximal direction. in order to maintain pre injection
needle safety and prevent exposure of the needle translation of the syringe in the
proximal direction due to this force has to be avoided. For this e the case may be
arranged to lock the detent mechanism prior to being translated in the proximal direction
ve to the chassis when the chassis is being pressed against the injection site so as
to avoid translation of the carrier. This may be achieved by a rib in the case preventing
deflection of the resilient beam of the detent mechanism by supporting it outwardly.
Translation of the case is translated into the advanced position in the proximal direction
3O on contact to the injection site is arranged to unlock the detent mechanism rendering it
operable. This may be achieved by the rib being moved with the case so as to no longer
outwardly supporting the resilient beam of the detent mechanism. In order to ensure
that the case is not moved in the al direction unlocking the detent mechanism
before the tive needle sheath is removed a cap may be attached to the proximal
end of the case so as to make the chassis inaccessible before the cap is removed. The
cap preferably engages the protective needle sheath by means of a barb in a manner to
remove the protective needle sheath when the cap is being pulled off the auto—injector.
In order to facilitate removal of the cap it may have a profiled surface mating with a
surface on the case so that the cap is pulled off when rotated. The barb may be
ted to the cap in a manner ng them to rotate independently so as to avoid
torque on the protective needle sheath when the cap is rotated in order not to distort the
1O needle inside the tive needle sheath.
The distally arranged trigger button may be at least initially coupled to the carrier,
wherein the case is arranged to abut the trigger button in the initial state ting
sion of the trigger button. On translation of the case into the advanced position
when the chassis is being pressed against the injection site the trigger button remains
coupled to the carrier thus emerging from the case which has been moved relative to
the chassis, carrier and trigger button so as to allow sion of the r button for
starting an injection cycle. Thus a sequence of operation is defined for the auto-injector
to be actuated, first pressing it against the injection site and then to push the trigger
button. This reduces the risk of finger stick injuries particularly if the user were to be
confused which end of the auto-injector to apply against their skin. Without a sequence
the user would risk inserting the needle into their thumb which is icantly less
probable with the forced sequence.
The syringe retraction control mechanism may comprise a second collar g against
the distal end of the control spring and having a resilient proximal beam with a second
beam head having an inward boss. The second beam head is arranged to be in a
ramped engagement with a second case detent in the case in a manner ramping the
second beam head in the inward direction under load of the control spring in the distal
direction. The inward boss is arranged to inwardly abut the carrier for preventing inward
deflection of the second beam head and keep the second collar locked to the case. A
third recess is arranged in the carrier for allowing the inward boss to be inwardly
deflected on translation of the case in the distal direction relative to the carrier on
removal of the auto-injector from the injection site.
In an ative embodiment the first collar and/or the second collar may also be
threaded to one of the components which they are intended to couple to the control
spring wherein the case would be arranged to prevent the threads from decoupling in
some relative longitudinal positions while ng the collar to rotate out of the ed
engagement in other relative longitudinal positions so as to allow the collars to switch to
the respective other ent to be coupled to the control spring.
in an alternative embodiment the trigger button may be arranged distally, wherein the
case is arranged as a wrap-over sleeve trigger having a closed distal end face covering
the trigger button. In an initial state a clearance is provided between the distal end face
of the sleeve trigger and the trigger button allowing for some travel of the sleeve trigger
’15 against the bias of the control spring in the proximal direction in a first phase before
abutting the trigger button. As soon as the sleeve r has contacted the trigger
button the trigger button is pushed by the sleeve trigger on further translation in a
second phase. This embodiment allows for keeping the majority of the components of
the auto-injector while oniy the bed es need mod ification aliowing to
customize a platform device to particular requirements. An auto—injector with a sleeve
trigger is particularly well suited for people with dexterity problems since, as d to
conventional art auto-injectors, triggering does not require operation of small buttons by
single fingers. Instead, the whole hand is used.
Retraction of the needle requires the user to lift the njector far enough from the
injection site to allow the case or sleeve trigger to translate back in the distal direction to
switch the l spring. As it may be difficult for the user to know if the injection is
finished or not a able feedback component may be provided, capable of, upon
release, generating an audible and/or tactile feedback to the user, wherein the feedback
component is arranged to be ed when the plunger reaches a position relative to
the syringe in which the stopper is located in proximity of a proximat end of the syringe,
is. when the injection is at least almost ed. The released feedback
, e.g.,
component then s on a housing component, such as the case, sleeve trigger or
r button indicating the end of the injection. Impacting a directiy accessibie
component ailows for high perceptibility of the noise and direct access to the user’s
hand or finger for generating the tactile feedback. Preferably the feedback component
may impact the trigger button which may be shaped as a drum for providing a loud
noise.
The needle extension length or depth is ably defined by the carrier ve to the
s not relative to the case, so if the user flinches or fails to hold the auto-injector
hard against the ion site, only the case will move in the distai direction while the
injection depth remains constant. As long as this case motion does not exceed a set
distance the case does not yet switch the control spring for needle retraction.
The auto-injector may be operated by a number of key mechanical operations:
— The case is advanced relative to the chassis compressing the l spring
giving the user the impression of depressing a skin interlock sleeve. All other
components remain in the same place during case advance resulting in the trigger
button appearing from the distal end of the case.
- The user pushes the trigger button which can now be operated. Button
depression directly moves the carrier and hence the drive sub—assembly in the
proximal direction a set distance until the control spring takes over via the first
collar and fully extends the needle, e.g. inserts the needle into the injection site.
- The trigger button stops on the distal end of the case as the carrier continues
translating in the proximal direction. The motion of the carrier relative to the trigger
button is used to release the drive spring just before full insertion depth is reached,
eg. by pulling a peg on the r button out of the r thus allowing the
plunger to move. The drive spring drives the plunger down the syringe barrel
expeliing the medicament.
~ A feedback mechanism is released when the piunger is near the end of travel
shortly before the stopper bottoms out in the syringe, providing audible and/or
e indicator of the end of injection to the user.
The needle remains fuliy extended until the user moves the case back a set
distance relative to the chassis at which point the second collar decouples from the
case and couples to the carrier while the first collar decouples from the carrier and
couples to the chassis thus allowing the control spring to retract the carrier and
hence the needle.
The auto—injector may ably be used for subcutaneous or intra-muscular injection,
particularly for delivering one of an analgetic, an anticoagulant, insulin, an insulin
derivate, heparin, Lovenox, a vaccine, a growth hormone, a peptide hormone, a
1O proteine, antibodies and complex carbohydrates. The auto-injector may preferably be
adapted to be used for ing a liquid medicament with high viscosity, e.g. liquid
solutions of antibody medicaments.
The term medicament", as used herein, means a pharmaceutical formulation
containing at least one ceutically active compound,
n in one embodiment the pharmaceutically active compound has a molecular
weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a
DNA, a RNA, a antibody, an enzyme, an antibody, a hormone or an oiigonucieotide, or
a mixture of the above-mentioned pharmaceuticaliy active nd,
wherein in a further embodiment the pharmaceutically active compound is useful for the
treatment and/or laxis of diabetes meliitus or complications associated with
es mellitus such as diabetic retinopathy, thromboembolism disorders such as
deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), ,
myocardial infarction, cancer, macuiar degeneration, inflammation, hay fever,
atherosclerosis and/or rheumatoid arthritis,
wherein in a further embodiment the ceutically active compound comprises at
least one peptide for the treatment and/or prophylaxis of diabetes us or
complications ated with diabetes mellitus such as diabetic retinopathy,
wherein in a r embodiment the pharmaceutically active compound comprises at
least one human insulin or a human insulin analogue or derivative, glucagon-like
peptide (GLP-i) or an analogue or derivative thereof, or exedin~3 or exedin—4 or an
analogue or derivative of exedin-S or exedin-4.
Insulin analogues are for example Gly(A21), Arg(BB1), Arg(B32) human insulin; Lys(BS),
9) human insulin; 28), Pro(829) human insulin; 8) human insulin;
human insulin, wherein proline in position 828 is ed by Asp, Lys, Leu, Val or Ala
and wherein in position 829 Lys may be replaced by Pro; Ala(826) human insulin;
1O Des(828-B30) human n; Des(BZ7) human insulin and Des(l330) human insulin.
Insulin derivates are for example BZQ—N-myristoyl-des(830) human insulin; BZQ-N-
palmitoyl-des(l330) human insulin; BZQ-N-myristoyl human insulin; palmitoyl
human insulin; B28-N~myristoyl LysBZBProBZQ human insulin; 828~N~palmitoyl~
LysBZSProBZQ human insulin; BBO-N-myristoyl-ThrBZQLysBBO human insulin; B30-N-
palmitoyl— ThrBZQLysBSO human n; BZQ-N-(N—palmitoyl-Y—glutamyl)-des(830)
human insulin; (N~lithocho|yI-Y-glutamyl)«des(BSO) human insulin; BZQ~N—(w-
carboxyheptadecanoyl)~des(830) human insulin and BZQ-N-(w-carboxyheptadecanoyl)
human insulin.
Exendin-4 for e means Exendin—4(1-39), a peptide of the ce H-His-Gly~
GIu-GIy—Thr—Phe-Thr—Ser—Asp-Leu-Ser—Lys-Gln—Met—Glu—GIu—G|u~Ala~Va|~Arg~Leu~Phe-
lle-Glu—Trp-Leu~Lys~Asn—Gly-Gly-Pro-Ser—Ser—GIy—AIa-Pro-Pro-Pro-Ser-NH2.
Exendin-4 derivatives are for example selected from the following list of compounds:
H~(l_ys)4-des Pr036, des Pr037 Exendin~4(1-39)-NH2,
H~(Lys)5-des Pr036, des Pr037 Exendin-4(1-39)—NH2,
des Pr036 [A5928] Exendin-4(1-39),
des Pr036 [IsoAsp28] Exendin~4(1~39),
des Pr036 [Met(O)14, Asp28] Exendin~4(1~39),
des Pr036 [Met(O)14, lsoAsp28] Exendin-4(1-39),
des Pro36 [Trp(02)25, Asp28] Exendin-4(1~39),
des Pro36 [Trp(02)25, lsoAsp28] Exendin-4(1-39),
des Pr036 )14 )25, Asp28] Exendin-4(’i—39),
des Pr036 [Met(O)14 Trp(02)25, lsoAspZS] Exendin-4(1-39); or
des Pro36 [Asp28] Exendin-4(1-39),
des Pr036 [IsoAsp28] Exendin-4(1-39),
des Pr036 [Met(O)14, Asp28] n—4(1~39),
des Pro36 [Met(0)14, lsoAsp28] n~4(1~39),
1O des Pro36 [Trp(02)25, Asp28] ExendEn-4(’i-39),
des Pro36 [Trp(02)25, isoAsp28] n—4(1—39),
des Pr036 [Met(O)14 Trp(02)25, Asp28} Exendin-4(1-39),
des Pr036 [Met(O)14 Trp(02)25, lsoAsp28] Exendin-4(1-39),
wherein the group -Ly36-NH2 may be bound to the C-terminus of the Exendin-4
tive;
or an Exendin~4 derivative of the sequence
H-(Lys)6-des Pr036 [Asp28] Exendin-4(1~39)—Lys6-NH2,
des Asp28 Pro36, Pr037, Pr038Exendin-4(1-39)—NH2,
H~(Lys)6-des Pr036, Pr038 [Asp28] Exendin~4(1~39)—NH2,
H-Asn-(Glu)5des Pr036, Pr037, Pr038 [Asp28] Exendin-4(1-39)-NH2,
des Pro36, Pro37, Pr038 [Asp28] Exendin-4(1-39)-(Lys)6—NH2,
)6-des Pro36, Pr037, Pr038 [Asp28] Exendin-4(1-39)—(Lys)6-NH2,
H-Asn-(Giu)5-des Pro36, Pr037, Pr038 [Asp28] Exendin-4(‘i~39)-(Lys)6-NH2,
H-(Lys)6—des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
H—des Asp28 Pr036, Pr037, Pr038 [Trp(02)25] Exendin-4(1—39)~NH2,
H-(Lys)6—des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin-4(1~39)~NH2,
H~Asn-(G|u)5-des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] n-4(1-39)—NH2,
des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6—NH2,
H-(Lys)6-des Pr036, Pr037, Pr038 [Trp(02)25, Asp28] Exendin~4(1-39)—(Lys)6-NH2,
H—Asn-(Glu)5-des Pr036, Pr037, Pr038 [Trp(O2)25, Asp28] Exendin~4(‘i~39)—(Lys)6—NH2,
H-(Lys)6-des Pr036 [Met(O)14, Asp28] Exendin-4(‘i—39)—LysG-NH2,
des Met(O)14 Asp28 Pr036, Pr037, Pr038 Exendin-4(1-39)—NH2,
H—(Lys)6—desPr036, Pr037, Pro38 [Met(O)14, Asp28] Exendin—4(1-39)-NH2,
H-Asn-(Glu)5-des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin-4(t-39)—NH2,
des Pr036, Pro37, Pro38 [Met(O)14, Asp28] Exendin~4(1~39)-(Lys)6~NH2,
)6-des Pr036, Pro37, Pr038 [Met(O)14, Asp28] Exendin-4(1-39)—(Lys)6—NH2,
H—Asn-(Glu)5 des Pr036, Pr037, Pr038 [Met(O)14, Asp28] Exendin~4(1~39)—(Lys)6—NH2,
H-LysS-des Pro36 )14, Trp(02)25, Asp28] Exendin-4(1-39)—Ly36-NH2,
H-des Asp28 Pro36, Pr037, Pr038 [Met(O)14, )25] Exendin-4(1-39)—NH2,
H~(Lys)6-des Pr036, Pr037, Pr038 [Met(O)l 4, Asp28] Exendin-4(1-39)—NH2,
‘10 H-Asn-(Glu)5-des Pr036, Pr037, Pro38 )14, Trp(02)25, Asp28] Exendin-4(1-39)-
NH2,
des Pr036, Pr037, Pr038 [Met(O)14, Trp(02)25, Asp28] Exendin-4(1~39)-(Lys)6-NH2,
H-(Lys)6~des Pr036, Pr037, Pr038 )14, Trp(02)25, Asp28] Exendin~4(S1-39)-
(Lys)6-NH2,
‘15 H-Asn-(Glu)5~des Pr036, Pr037, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)—
(Lys)6-NH2;
or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned
Exedin~4 derivative.
es are for example hypophysis hormones or hypothalamus hormones or
regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
Chapter 50, such as Gonadotropine (Follitropin, Lutropin, ngonadotropin,
Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, relin,
Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
A polysaccharide is for example a aminoglycane, a hyaluronlc acid, a heparin, a
low molecular weight heparin or an ultra low molecular weight heparin or a derivative
thereof, or a ted, eg. a poly-sulphated form of the above-mentioned
polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a
pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is
enoxaparin sodium.
Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
Acid addition salts are e.g. HCI or HBr salts. Basic salts are e.g. salts having a cation
selected from alkali or alkaline, e.g. Na+, or K+, or 032+, or an ammonium ion
N+(R‘i)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen,
an ally substituted Ct-C6-alkyl group, an optionally substituted C2—C6~alkenyl
group, an optionally substituted CG-C10-aryl group, or an optionally substituted 06
heteroaryl group. Further examples of pharmaceutically acceptable salts are described
in "Remington's Pharmaceutical Sciences" 17. ed. Alfonso R. o (Ed), Mark
Publishing Company, , Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical
Tech nology.
Pharmaceutically acceptable solvates are for example hydrates.
The drive spring and control spring may be compression springs. However, they may
likewise be any kind of stored energy means such as torsion s, gas springs etc.
Further scope of applicability of the present invention will become apparent from the
detailed ption given hereinafter. However, it should be tood that the
detailed description and ic examples, while indicating red embodiments of
the invention, are given by way of illustration only, since various changes and
modifications within the spirit and scope of the invention will become apparent to those
skilled in the art from this detailed description.
Brief Description of the Drawings
The present invention will become more fully understood from the detailed description
given hereinbelow and the accompanying drawings which are given by way of
3O illustration only, and thus, are not limitive of the present invention, and wherein:
Figure 1 shows two longitudinal sections of an auto-injector in different section
planes in a state priorto use,
Figure 2 shows two longitudinal sections of the auto~injector after removal of a
cap and a tive needle sheath,
Figure 3 shows two longitudinal sections of the auto-injector with the case
moved in al direction relative to the chassis,
1O Figure 4 shows two longitudinal sections of the auto—injector with a r
button depressed,
Figure 5 shows two longitudinal sections of the auto-injector during needle
extension,
Figure 6 shows two longitudinal sections of the auto—injector with the needle in
extended proximal on,
Figure 7 shows two longitudinal sections of the auto-injector during ing the
medicament,
Figure 8 shows two longitudinal sections of the auto—injector where the stopper
is located in proximity of a proximal end of the syringe,
Figure 9 shows two longitudinal sections of the auto-injector where the case is
moved in distal direction relative to the chassis,
Figure 10 shows two longitudinal sections of the auto~injector with the needle
retracted into a needle safe position,
Figure 11 shows schematic views of a detent mechanism for controlling
movement of a carrier relative to a chassis of the auto-injector in four
different states,
Figure 12 shows schematic views of a needle extension control mechanism for
controlling movement of a first collar in six different states,
Figure 13 shows schematic views of a syringe retraction control mechanism in
three different states
Figure 14 shows schematic views of a feedback release mechanism for audibly
and/or tactily indicating the end of injection in three ent states,
Figure 15 shows schematic views of a r release mechanism in three
different states,
Figure 16 shows tic views of a button e ism in three
ent states,
Figure 17 is an isometric view of an alternative embodiment of the plunger
release mechanism,
Figure 18 is a longitudinal section of an alternative embodiment of the button
reiease mechanism,
Figure 19 shows longitudinal sections of an alternative embodiment of the detent
mechanism,
Figure 20 is a longitudinal section of a third embodiment of the detent
mechanism,
Figure 21 is a longitudinal section of an alternative embodiment of the feedback
release mechanism,
Figure 22 shows longitudinal sections of an ative ment of the needle
extension control mechanism, also arranged to perform the function of
the detent ism on needle retraction and needle extension,
Figure 23 is an isometric View of the needle extension control mechanism of
figure 22,
Figure 24 shows udinal sections of a third embodiment of the needle
extension control mechanism, also arranged to perform the functions
of the detent ism,
Figure 25 is an isometric view of the needle extension control mechanism of
figure 24,
Figure 26 shows longitudinal sections of a third embodiment of the feedback
release mechanism, and
Figure 27 is another embodiment of the auto-injector having a wrap-over sleeve
trigger instead of a trigger button.
Corresponding parts are marked with the same reference symbols in all figures.
Detailed Description of red Embodiments
A ramped engagement in the terminology of this specification is an engagement
between two components with at least one of them having a ramp for engaging the
other component in such a manner that one of the components is flexed aside when the
ents are axially pushed t each other provided this component is not
prevented from flexing aside.
Figures 1a and 1b show two longitudinal sections of an auto-injector 1 in different
section planes, the ent section planes approximately 90° rotated to each other,
wherein the auto~injector 1 is in an initial state prior to ng an injection. The auto-
lnjector 1 comprises a chassis 2. In the following the chassis 2 is generally considered
as being fixed in position so motion of other components is described relative to the
chassis 2. A syringe 3, eg. a Hypak e, with a hollow injection needle 4 is
arranged in a proximal part of the auto—injector 1. When the auto-injector 1 or the
e 3 is led a protective needle sheath 5 is attached to the needle 4. A
stepper 6 is arranged for sealing the e 3 distally and for displacing a liquid
medicament M through the hollow needle 4. The syringe 3 is held in a tubular carrier 7
and supported at its proximal end therein. The carrier 7 is slidably arranged in the
chassis 2.
A drive spring 8 in the shape of a compression spring is arranged in a distal part of the
carrier 7. A plunger 9 serves for forwarding the force of the drive spring 8 to the
stopper 6.
The drive spring 8 is loaded between a distal r end face 10 of the carrier 7 and a
thrust face 11 arranged distally on the plunger 9.
The carrier 7 is a key element housing the syringe 3, the drive spring 8 and the plunger
9, which are the components required to expel the medicament M from the syringe 3.
These components can therefore be referred to as a drive sub—assembly.
The chassis 2 and the carrier 7 are arranged within a tubular case 12. A trigger button
13 is ed at a distal end of the case 12. in a plunger release mechanism 27 a peg
14 protrudes from a distal end face of the trigger button 13 in the proximal direction P
between two resilient arms 15 originating from the distal carrier end face 10 thus
preventing them from flexing s each other in an initial state A illustrated in figure
15A. ln figure 15A only one of the resilient arms 15 is shown to illustrate the principle.
Outwardly the resilient arms 15 are caught in respective first recesses 16 in a distal
plunger sleeve 17 attached ly to the thrust face 11 and arranged inside the drive
spring 8. The engagement of the resilient arms 15 in the first recesses 16 prevents axial
translation of the plunger 9 relative to the carrier 7. The resilient arms 15 are ramped in
a manner to flex them inwards on reiative motion between the plunger 9 and the r
7 under load ofthe drive spring 8, which is ted by the peg 14 in the initial state A.
The r 7 is locked to the chassis 2 for preventing relative translation by a detent
mechanism 18 illustrated in more detail in figures 11A to 11D.
The trigger button 13 is initially engaged to the case 12 by a button release mechanism
26 and cannot be depressed. The button release mechanism 26 is illustrated in detail in
figures 16A to 16C. Referring now to figure 16A the button release mechanism 26
comprises a resilient proximal beam 13.1 on the trigger button 13, the proximal beam
13.1 having an outward first ramp 13.2 and an inward second ramp 13.3. in an initial
state A illustrated in figure 16A the outward first ramp 13.2 is engaged in a ramped first
case detent 12.1 preventing the trigger button 13 from moving out of the distal and D.
The trigger button 13 aliy abuts both the case 12 and the carrier 7 hence being
prevented from being depressed in the proximal direction P.
Referring again to figures 1A and 18 a control spring 19 in the shape of r
compression spring is arranged around the carrier 7 and acts between a al first
collar 20 and a distal second collar 21. The l spring 19 is used to move the carrier
7 and hence the drive sub-assembly in the proximal direction P for needle extension or
in the distal direction D for needie tion.
In the state as delivered as shown in figures 1a and 1b a cap 22 is attached to the
proximai end ofthe case 12 and the protective needle sheath 5 is still in piace over the
needle 4 and the needie hub. An inner sleeve 22.1 of the cap 22 is arranged inside the
chassis 2 and over the protective needle sheath 5. In the inner sleeve 22.1 a barb 23 is
attached. The barb 23 is engaged to the protective needle sheath 5 for joint axial
ation.
A sequence of operation of the auto-injector 1 is as follows:
A user pulls the cap 22 from the proximal end of the case 12. The barb 23 joins the
protective needle sheath 5 to the cap 22. Hence, the protective needle sheath 5 is also
removed on removal of the cap 22. s 2a and 2b show the njector 1 with the
cap 22 and needle sheath 5 removed. The carrier 7 and syringe 3 are prevented from
moving in the proximal direction P by the detent mechanism 18 being in a state A as in
figure 11A. Referring now to figure 11A, the detent mechanism 18 comprises a resilient
beam 2.1 on the chassis 2 with an inwardly ding first beam head 2.2. The first
beam head 2.2 has a proximal third ramp 2.3. The detent mechanism 18 further
ses a rhomboid ramp member 7.1 on the carrier 7 having a proximal fourth ramp
7.2 and a distal fifth ramp 7.3. In state A a rounded off distal side of the first beam head
2.2 abuts the ramp member 7.1 in the distal direction D resisting movement of the
carrier 7 in the proximal direction P relative to the chassis 2. A rib on the case 12 is
provided for preventing outward deflection of the resilient beam 2.1 y also
preventing motion of the r 7 relative to the chassis 2.
Referring again to figures 2A and 2B the user grabs the case 12 and places the chassis
2 protruding from the case 12 at the proximal end P against an injection site, eg. a
patient’s skin. As the auto-injector 1 is pressed against the injection site the case 12
translates in the proximal direction P relative to the chassis 2 into an advanced position
as illustrated in figures 3A and 3B. The second collar 21 is locked to the case 12 and is
moved with the case 12 relative to the chassis 2 and relative to nearly all other
components of the njector 1 thus slightly compressing the control spring 19
against the first collar 20 which is prevented from moving in the proximal direction P by
the chassis 2 due to a needle extension control mechanism 24 being in a state A
illustrated in detail in figure 12A. Referring now to figure 12A, a resiiient member in the
shape of an arrowhead 20.1 is proximally arranged on the first collar 20. The first collar
with the arrowhead 20.1 is being forced in the proximal direction P under load of the
compressed control spring 19. An d sixth ramp 20.2 on the arrowhead 20.1
interacts with a second distal seventh ramp 2.4 on the chassis 2 ramping the arrowhead
.1 in an inward ion [which is prevented by the arrowhead 20.1 inwardly abutting
the carrier 7. Hence. the first collar 20 cannot translate in the proximal ion P.
Referring again to figures 3A and 3B the second collar 21 is locked to the case due to a
syringe retraction control mechanism 25 being in a state A illustrated in detail in figure
13A. Referring now to figure 13A, the syringe retraction control mechanism 25
comprises a resilient proximal beam 21 .t on the second collar 21, the proximal beam
1O 21.1 having a second beam head 21.2 having an inward boss 21.3 and a distal outward
eighth ramp 21.4. The distal outward eighth ramp 21.4 is engaged in a ramped second
case detent 12.2 in a manner ramping the second beam head 21.1 in the inward
direction I with the second collar 21 under load of the control spring 19 in the distal
direction D which is ted by the inward boss 21.3 inwardly abutting the carrier 7.
Referring again to figures 3A and BB, if the user was to move the case 12 away from
the injection site, the control spring 19 s returning the auto-injector 1 to the initial
ion after removal of the cap 22 as illustrated in figures 2A and 28.
In the state as in figures 3A and 3B the carrier 7 continues to be prevented from moving
in the proximal direction P by the detent mechanism 18, however with the case 12 in its
advanced on the detent mechanism 18 is unlocked as the rib on the case 12 has
also moved and no longer prevents outward deflection of the resilient beam 2.1.
Movement of the case 12 relative to the carrier 7, which is locked to the chassis 2 by the
detent mechanism 18, causes the button release mechanism 26 to switch to a state B
illustrated in figure 16B. The trigger button 13 cannot translate with the case 12 in the
proximal direction P as it is abutted against the carrier 7. The ramp on the first case
detent 12.1 interacts with the outward first ramp 13.2 on the proximal beam 13.1 on the
r button 13 deflecting the proximal beam 13.1 in the inward direction I thus
engaging the inward second ramp 13.3 on the proximal beam 13.1 in a ramped r
detent 7.4 arranged in the carrier 7. As the case 12 is translated further in the proximal
direction P it ts the proximal beam 13.1 outwardly thus locking the trigger button
13 to the carrier 7. The trigger button 13 now protrudes from the distal end D of the
chassis 12 and is ready to be pressed.
In the state as in figures 3A and SB the user depresses the r button 13 in the
proximal direction P. As the trigger button 13 abuts against the carrier 7 the carrier 7 is
pushing in the proximal direction P against the chassis 2, the carrier 7 and the chassis 2
interacting in the detent mechanism 18. The force exerted by the user ng the
trigger button 13 is ed through the chassis 2 onto the injection site, not between
the trigger button 13 and the case 12. The detent mechanism 18 provides a resistive
1O force when the user pushes the trigger button 13. Once the user applies a force which
exceeds a pre-determined value the detent mechanism 18 releases, initiating the
injection cycle. Referring now to figure 11B showing the detent mechanism 18 in a state
B, the resilient beam 2.1 on the chassis 2 begins to bow under load from the rhomboid
ramp member 71 on the carrier 7, g elastic . Despite the proximal fourth
ramp 7.2 on the ramp member 7.1 friction between the contacting faces of the first
beam head 2.2 and the proximal fourth ramp 7.2 prevents movement of the first beam
head 2.2 in the outward direction 0 until the htening force in the resiliently
deformed beam 2.1 is sufficiently large to overcome it. At this point the resilient beam
2.1 is deflected in the outward direction 0 moving out of the way of the carrier 7 thus
allowing the carrier 7 to translate in the proximal direction P. When the carrier 7 travels
sufficiently far in the ai direction P the id ramp member 7.1 on the carrier
7 passes under the first beam head 2.2 thus allowing it to relax and move back in the
inward direction 1 distally behind the rhomboid ramp member 7.1 in a state C iliustrated
in figure 110 at the same time constraining transiation of the carrier 7 in the distal
direction D ve to the chassis 2.
Once the carrier 7 siides far enough in the proximal direction P relative to the first collar
the needle extension control mechanism 24 is switched to a state B as illustrated in
figure 128. in figure 128 the carrier 7 has been translated in the proximai direction P in
such a mannerthat the arrowhead 20.1 on the first collar 20 is no longer inwardly
supported. This may be achieved by a second recess 7.5 in the carrier 7. The
arrowhead 20.1 is now deflected in the inward direction I into the second recess 7.5
under load of the control spring 19 arriving at a state C as illustrated in figure 120. The
first collar 20 is now led from the chassis 2. d, the arrowhead 20.1 couples
the first collar 20 to the carrier 7 by an inward ninth ramp 20.3 engaging a distal tenth
ramp 7.6 on the carrier 7 at the proximal end of the second recess 7.5. Hence, the
l spring 19 continues moving the carrier 7 in the proximal direction P from this
point. Whilst the user advances the needle 4 by a proportion of its travel, the control
spring 19 takes over insertion before the needle 4 protrudes from the proximal end P.
Therefore the user experience is that of pressing a button, ratherthan manually
inserting a needle.
The detent mechanism 18 relies on the user applying a force rather than a displacement.
Once the force applied exceeds the force ed to switch the detent the user will
push the trigger button 13 fully, ensuring that the first collar 20 will always switch. if the
user fails to pass the detent, the trigger button 13 returns to its unused state ready for
use as illustrated in s 3A and BB. This feature avoids the auto-injector 1 arriving in
an undefined state.
Figures 4A and 4B show the autowinjector1 with the trigger button 13 depressed
sufficiently for the l spring 19 to couple on to the carrier 7 and continue moving
the carrier 7 forwards, but not yet abutting the case 12.
The carrier 7 d to the first collar 20 is ated in the proximal direction P driven
by the control spring 19. As the syringe 3 is arranged for joint axial translation with the
carrier 3 the syringe 3 and needle 4 are also translated resulting in the needle 4
protruding from the proximal end P and being inserted into the injection site. The trigger
button 13 returns to its initial position relative to the case 12 and latches back to the
case 12 from the carrier 7 as in state A in figure 16 A. The carrier 7 translates further in
the proximal direction P preventing inward deflection of the proximal beam 13.1 so the
outward first ramp 13.2 cannot disengage from the first case detent 12.1.
immediately prior to the needle 4 reaching full ion depth as illustrated in figures 5A
and SB the peg 14 on the trigger button 13 is completely pulled out from between the
resilient arms 15 on the carrier 7. Hence, the plunger release mechanism 27 arrives in a
state 8 shown in figure 158 with the resilient arms 15 no longer inwardly supported by
the peg 14. Due to the ramped engagement of the ent arms 15 in the first recess
16 they are deflected in the inward direction I under load of the drive spring 8 arriving in
a state B illustrated in figure 15C. Hence, the plunger 9 is ed from the carrier 7
and driven in the proximal direction P by the drive spring 8, ready to expel the
ment M. The force to pull the peg 14 out from between the resilient arms 15 is
provided by the control spring 19 while the force required to deflect the resilient arms 15
out of engagement to the piunger 9 is provided by the drive spring 8.
White the plunger 9 moves and closes a gap to the stopper 6 the movement of the
carrier 7 in the al direction P is completed by the control spring 19 pushing the
first collar 20. As the carrier 7 moves with respect to the chassis 2 during needle
extension the needie extension mechanism 24 arrives in a state D iilustrated in figure
12D. The ead 20.1 has moved with the carrier 7 and is still kept inwardly
deflected by the chassis 2 thus preventing the first collar 20 from disengaging the carrier
7. The arrowhead 20.1 must be able to t in the outward direction 0 to allow
retraction which will be discussed below. In order to allow outward deflection the
arrowhead 20.1 travels proximally beyond the part of the chassis 2 shown in figures 12A
to 12i= next to an aperture 2.5 in the s 2. However, as long as the case 12 is
being kept pressed t the injection site and not allowed to return in the distal
direction D beyond a predefined distance under load of the control spring 19 the
arrowhead 20.1 will be kept from deflecting in the outward direction 0 by a first rib 12.3
on the case 12 (not illustrated in s 12A to F, see figures 5A to 8A) during about the
second half of its motion for needle extension.
The needle 4 is now fully inserted into the injection site as illustrated in figures 6A and
GB. The time between the trigger button 13 pressed and the needle 4 being fully
inserted is very short, however several mechanical operations take place in this time.
3O The needle extension depth is defined by the carrier 7 relative to the chassis 2 not
relative to the case 12, so if the user flinches or fails to hold the auto—injector 1 hard
against the skin, only the case 12 will move in the distal direction D while the ion
depth s constant.
As soon as the plunger 9 has closed the gap to the stopper 6 under force of the drive
spring 8 the stopper 6 is pushed in the proximal direction P within the syringe 3
displacing the medicament M through the needle 4.
immediately prior to the end of expelling the medicament with the stopper 6 having
almost bottomed out in the syringe 3 as illustrated in figures 7A and 78 a feedback
1O ent 28 is released. The stack up of tolerances, most notably due to the syringe
3 requires that the feedback must always be ed prior to fuliy expelling the
medicament. ise, with certain combinations of parts, the feedback would not
always release. The feedback component 28 comprises an elongate portion 28.1
arranged within the distal plunger sleeve 17 and a distal end plate 28.2 arranged
between the carrier end face 10 and an end face of the trigger button 13. Two second
ent arms 30 originate from the distal carrier end face 10 and extend in the proximal
direction P. A feedback spring 29 is ed to bias the feedback component 28 in the
distal direction D relative to the carrier 7 by proximaily bearing against a rib on the
second resilient arms 30 and distally against the feedback component 28 (not
iilustrated).
Note: the feedback ent 28 is not illustrated in figures 16A, B and C for clarity
since it does not affect the function of the button release ism 26. A feedback
release mechanism 31 for releasing the feedback component 28 is schematically
illustrated in figures 14A, 14B and 14C. Referring now to figure 14A, the feedback
release mechanism 31 ses the second resilient arms 30. A ramped inward boss
.1 is ed on each second resilient arm 30 which is engaged to a respective
outward eleventh ramp 28.3 on the elongate portion 281 of the ck component 28
in such a manner that the second resilient arm 30 is deflected in the outward direction 0
3O under load of the feedback spring 29. in an initial state A of the feedback release
mechanism 31 the second resilient arms 30 are prevented from being outwardly
deflected by outward support of the distal plunger sleeve 17 thus preventing translation
of the feedback component 28 relative to the carrier 7. The feedback release
mechanism 31 remains in state A until immediately priorto fully expelling the
medicament with the stopper 6 having almost bottomed out in the syringe 3 as
illustrated in figures 7A and 78. At this point the plunger 9 has been translated in the
al ion P relative to the carrier 7 to such an extent that the second resilient
arms 30 are no longer supported by the distal plunger sleeve 17. The ck release
mechanism 31 has thus arrived in a state B illustrated in figure 14B. Due to the ramped
engagement between the ramped inward boss 30.1 and the outward th ramp
28.3 the second resilient arm 30 is outwardly deflected under load of the feedback
1O spring 29 thus disengaging the feedback component 28 from the carrier 7 and allowing
the feedback component 28 to move in the distai direction D driven by the feedback
spring 29 in a state C illustrated in figure 140. Hence, the feedback component 28 is
rated in the distal direction D and the distal end plate 28.2 impacts on the inside
of the trigger button 13 producing audible and tactile feedback to the user that expelling
the medicament is about finished.
Figures 8A and BB show the auto-injector1 with the stopper 6 having entirely bottomed
out in the syringe 3.
As ned above the user is able to let the case 12 move by a few millimetres in the
distal direction D under the force of the control spring 19 t affecting the position of
the needle 4 as long as that motion is below a predefined distance. lfthe user wishes to
end the injection, at any time, they must allow the case 12 to move in the distal direction
D beyond that ce. Figures 9A and 9B show the auto-injector 1 with the chassis
extended, eg. when lifted from the injection site with the case 12 moved all the way in
the distal ion D so that the chassis 2 protrudes from the proximal end of the case
12. As the case 12 is moved the first collar 20 releases the carrier 7 and then the
second collar 21 releases from the case 12 and pulls the carrier 7 in the distal direction
D. The sequencing of this switching is critical as retraction will fail if both collars 20, 21
are attached to the carrier 7 at the same time. This is overcome by ting the
switching of the collars 20, 21 by a significant dispiacement of the case 12.
The switching ofthe first collar 20 is illustrated in figures 12E and F. In figure 12E the
case 12 has been allowed to move in the distal direction D under load of the l
spring 19, e.g. during removal of the auto-injector1 from the injection site. The first rib
12.3 (not illustrated, see figure 9A) is removed from outwardly behind the arrowhead
.1. The first collar 20 is still being pushed in the proximal direction P by the control
spring 19. Due to the engagement of the inward ninth ramp 20.3 on the arrowhead 20.1
with the distal tenth ramp 7.6 on the carrier 7 the arrowhead 20.1 is deflected in the
outward ion 0 into the aperture 2.5 of the chassis 2 (illustrated in figures 12A to
12F), the needle extension control mechanism 24 arriving in a state E as illustrated in
figure 12E, decoupling the first collar 20 from the carrier 7 and latching it to the chassis
As the case 12 is moving further in the distal ion D relative to the chassis, e.g. on
removal from the ion site, the syringe retraction control mechanism 25 switches
from its state A (cf. figure 13A) into a state B illustrated in figure 138. The case 12 and
the second collar 21 locked to the case 12 move together in the distal direction D while
the carrier 7 is held in place by the detent mechanism 18 in its state C as described
above (of. figure 110). Due to this motion the inward boss 21.3 on the second beam
head 21.2 of the proximal beam 21.1 on the second collar 21 no longer inwardly abuts
the carrier 7. d the inward boss 21.3 is deflected in the inward direction I into a
third recess 7.7 in the carrier 7 due to the ramped ment of the second beam
head 21.1 to the ramped second case detent 12.2 under load of the l spring 19.
The syringe retraction l mechanism 25 thus arrives in a state C as illustrated in
figure 130 with the second collar 21 decoupled from the case 12 and coupled to the
carrier 7. The detent mechanism 18 applies a small retarding force to the movement of
the carrier 7 before the syringe retraction control mechanism 25 switches to state C as
there is a small sliding force, applied by the second collar 21, pulling the carrier 7 in the
distal direction D on translation of the case 12 in the distal direction D when the needle
extension control mechanism 24 has already been switched into state E. If the carrier 7
moves too far in the distal direction D before the second collar 21 switches, the case 12
runs out of travel before the inward boss 21.3 can t into the third recess 7.7
preventing retraction.
Starting from the position C of the detent ism 18 (cf. fig. 11C) the carrier 7 and
hence the rhomboid ramp member 7.1 are translated in the distal direction D under load
of the control spring 19. Hence, the distal fifth ramp 7.3 of the rhomboid ramp member
7.1 engages the proximal third ramp 2.3 on the first beam head 2.2 of the resilient beam
2.1 in a manner deflecting the resilient beam 2.1 in the inward direction I. This s
the small retarding force to the movement of the carrier 7 required for ensuring the
switching ofthe second collar 21 to the r 7. The resilient beam 2.1 and the
rhomboid ramp member 7.1 are offset sideways to allow the ent beam 2.1 to pass
without contacting the rhomboid ramp member 7.1 as soon as the first beam head 2.2 is
entirely inwardly from the ramp member 7.1 in a state D illustrated in figure 11D.
The control spring 19 is grounded at its proximal end in the case by the first collar 20
being abutted against the chassis 2. The distal end of the control spring 19 moves the
second collar 21 in the distal direction D taking with it the carrier 7 and hence the
syringe 3 with the needle 4 overcoming the detent mechanism 18 as illustrated in
figure 11D. Note that the needle 4 is retracted by the auto-injector 1 as soon as the user
allows the case 12 to translate sufficiently far as opposed to auto-injectors with needle
shields which require the user to remove the auto~injector from the injection site thereby
themselves pulling the needle out of the skin for allowing the needle shield to e.
As the movement allowed of the ck component 28 is limited ve to the carrier
7 it is no longer in contact with the trigger button 13 which has moved in the distal
direction D with the case 12 on removal from the ion site.
When the retraction begins the feedback spring 29 does not provide any retarding force.
Once the feedback component 28 hits the trigger button 13 again on retraction of the
carrier 7 the feedback spring 29 must be recompressed, reducing the force driving the
final part of retraction. In order to ensure a reliable retraction e this reducing force
the control spring 19 must be appropriately dimensioned.
The retraction ends when the distal collar 21 meets a first back stop 12.4 on the case 12
as in figures 10A and 10B. The arrowhead 20.1 on the first collar 20 is inwardly
ted by the carrier 7 in a state F rated in figure 12F and thus prevented from
deflecting in the inward direction 1. The outward sixth ramp 20.2 of the arrowhead 20.1
is engaged behind the first rib 12.3 on the case 12 preventing the case 12 from being
pushed in the proximal direction P again. A clearance may be provided between the
arrowhead 20.1 and the first rib 12.3 to allow fortolerances.
The detent ism 18 returns to state A as in figure 11A locking the carrier 7 in
on relative to the chassis 2 as it did initially, however it cannot be unlocked now as
the case 12 cannot move relative to the chassis 2.
A tab 20.4 on the first collar 20 is now visible through an indicator window 32 in the case
12 -— indicating the njector 1 has been used.
Figure 17 is an isometric View of an alternative embodiment of the r reiease
mechanism 27. The plunger release mechanism 27 prevents movement of the plunger
9 in the proximal direction P relative to the carrier 7 until the carrier 7 is moved in the
proximai direction P for needle extension. As d to the plunger release
2O mechanism 27 of figure 15, where relative movement of the carrier 7 and r
button 13 are used to r the release of the plunger 9, the alternative embodiment of
figure 17 releases the plunger 9 by movement of the carrier 7 ve to the second
collar 21. Figure 17 illustrates the plunger release mechanism 27 prior to plunger
release. The second collar 21 is shown transparent to improve clarity. The plunger 9 is
being pushed in the proximal direction P by the drive spring 8. In order for the plunger 9
to advance, it must rotate around a twelfth ramp 7.8 on the carrier 7. A ramp member
9.1 on the plunger 9 is arranged to engage this twelfth ramp 7.8. Rotation of the ramp
member 9.1 is blocked by an inward longitudinai rib 21.5 on the second collar 21
splined in a longitudinal aperture 7.9 in the carrier 7. The case 12 and the second collar
3O 21 remain in the same position, is coupled to each otherforjoint axial translation. On
depression of the r button 13 the carrier 13 and the plunger 9 being part of the
drive sub-assembiy are moved in the proximal direction P, first by the user pressing the
trigger button 13 and then by the controi spring 19 taking over via the first collar 20 as
described above. Once the carrier 7 moves sufficiently far in the proximal direction P
relative to the second collar 21 the ramp member 9.1 on the collar 9 comes clear of the
longitudinal rib 21.5 on the second collar 21 and can rotate past the proximal end of the
longitudinal rib 21.5 due to its ramped engagement to the twelfth ramp 7.8 under load of
the drive spring 8. Hence, the drive spring 8 advances the plunger 9 in the proximal
ion P for expelling the medicament M.
Figure 18 is a longitudinal section of an alternative embodiment of the button release
ism 26. Other than the button release mechanism 26 of figure 16 which gives
the appearance of a revealing trigger button 13 on skin contact by ing the ground
of the trigger button 13 between the carrier 7 and the case 12, the button release
ism 26 of figure 18 starts with the trigger button 13 locked but protruding from
the distal end of the case 12. Once the carrier 7 has moved in the distal direction D on
skin t of the chassis 2, it is possible to s the trigger button 13 and activate
the auto-injector 1. This ensures a sequenced operation.
In the embodiment of figure 18 the trigger button 13 has two proximal beams 13.1, each
of them having a ramped outward boss 13.4. In the initial state shown in figure 18 the
ramped outward bosses 13.4 are engaged in respective fourth recesses 12.5 in the
case 12. Disengaging the ramped outward bosses 13.4 from the fourth es 12.5 is
ted by the carrier 7 inwardly supporting the proximal beams 13.1 in a manner to
keep the proximal beams 13.1 from deflecting ly. inward protrusions 13.5 on the
proximal beams 13.1 abut against a second rib 7.10 on the carrier 7 in a manner
preventing the carrier 7 from moving further in the al direction P in the initial state.
Once the carrier 7 has moved in the distal direction D on skin contact of the chassis 2 a
first window 7.11 in the carrier 7 is moved behind the inward protrusion 13.5 so as to
allow the proximal beams 13.1 to be inwardly deflected due to their ramped
engagement in the fourth recesses 12.5 on depression of the trigger button 13. The
proximal beams 13.1 are now outwardly supported by the case 12 and remain engaged
to the carrier 7 even on retraction of the needle 4. The trigger button 13 does therefore
not return to its initial position, indicating that the auto~injector 1 has been used.
The button release mechanism 26 illustrated in figure 18 may preferably be combined
with the plunger release mechanism 27 illustrated in figure 17.
Figures 19A and 198 show two longitudinal sections of an ative embodiment of
the detent ism 18. The detent mechanism 18 of figures 11A to 11D, which may
be referred to as a "race track” mechanism because of the first beam head 2.2 travelling
around the rhomboid ramp member 7.1 has multiple functions which control the
movement of the r 7 ve to the chassis 2. The alternative detent mechanism
1O 18 of figures 19A and 19B uses three clips 7.12, 7.13, 2.6 to produce the same effect.
The first clip 7.12 is arranged as an outwardly biased resilient beam on the carrier 7
ing from the carrier 7 in the proximal direction P. the first clip 7.12 is arranged to
prevent the carrier 7 from being moved in the proximal direction P prior to the chassis 2
being sed or rather the case 12 being translated on skin contact. The first clip
7.12 is composed of two sections side by side. A first section 7.14 prevents nt
of the carrier 7 in the proximal direction P by abutting the chassis 2 in a recess. A
second section 7.15 is arranged as an outwardly ding clip head ed to be
ramped inwards by a ramp feature 12.6 on the chassis 12 for releasing the first clip 7.12
thereby ing the carrier 7 from the chassis 2 when the case 12 is being translated
in the proximal direction P on skin contact. A longitudinal slot 2.7 in the chassis 2 is
arranged for allowing the second section 7.15 to slide in the proximal direction P once
the lock has been released. A slight friction force between the first clip 7.12 and the
chassis 2 provides the retarding force required to ensure retraction.
The second clip 7.13 is ed as a resilient beam on the carrier 7 extending in the
distal direction D having an outwardly protruding third beam head 7.16 with a proximal
ramp. The third beam head 7.16 serves as a back stop against a third rib 2.9 on the
chassis 2 for preventing the carrier 7 moving in the distal direction D from its initial
position. The carrier 7 and chassis 2 are assembled with the second clip 7.13 in this
position prior to inserting the syringe 3 into the carrier 7 which is facilitated by the
proximal ramp on the third beam head 7.16. The syringe 3 locks the clip in place by
preventing inward deflection thus creating a fixed stop.
The third clip 2.6 is a resilient beam on the chassis 2 extending in the distal direction D.
A ramped fourth beam head 2.8 on the third clip 2.6 is ed to ly engage in a
fifth recess 7.17 in the carrier 7. Once the first clip 7.12 is unlocked, the user can load
the third clip 2.6 by ng the carrier 7 in the proximal ion P on depression of
the trigger button 13. The third clip 2.6 is loaded in compression, i.e. it will bend
outwards and release suddenly due to its ramped engagement to the carrier 7 ing
the detent onality similar to that illustrated in figure 11B.
Figure 20 is a udinal section of a third embodiment of the detent mechanism 18
which is a variation on the embodiment of figures 19A and 19B. In this embodiment the
detent function of the third clip 2.6 has been added into the first ciip 7.12. The iock
between the case 12 and the carrier 7 is released in the same way, but the detent is
provided by deflecting the first clip 7.12 inwards a second level which is achieved by the
chassis 2 not having a slot 2.7 for the second section 7.15. Instead the second section
7.15, once ramped inwards by the ramp feature 12.6 on the case 12 has to be further
ramped inwards inside the chassis 2 on axial load between the chassis 2 and the carrier
7, suddenly releasing their engagement.
Figure 21 is a longitudinal section of an alternative ment of the feedback reiease
mechanism 31. As opposed to the ck release mechanism 31 of figure 14 where
the feedback spring 29 acts between the carrier 7 and the feedback component 28, in
the embodiment illustrated in figure 21 the feedback spring 29 acts between the case 12
and the feedback component 28. During needle extension the ck spring 29 is
compressed as the feedback component 28 moves with the carrier 7 relative to the case
12. When the feedback component 28 is released by the piunger 9 shortly before the
end of dose, the feedback component 28 moves in the distal direction D and impacts
the trigger button 13. Other than in figure 14 the feedback spring 29 is not being
recompressed during needle retraction since it is grounded in the case 12 not in the
carrier 7.
Figures 22A and 228 show longitudinal sections of an ative embodiment of the
needle extension control mechanism 24 which is also arranged to perform the detent
function ofthe detent mechanism 18 on needle retraction and needle extension. Figure
23 shows a corresponding isometric view. A fourth clip 20.5 on the first collar 20 is
arranged as a resilient beam with a beam head having an inward al thirteenth
ramp 20.6 for engaging a fourth rib 7.18 on the carrier 7 and outwardly ted by the
case 12 so as to keep the first collar 20 engaged to the carrier 7 prior to use, during
needle extension and during expelling the ment. When the case 12 moves in
distal direction relative to the carrier, e.g. when the user lifts the case 12 away from the
injection site at the end of injection, a sixth recess 12.7 in the case 12 is moved
outwardly behind the fourth clip 20.5 allowing the fourth clip 20.5 to release when the
carrier 7 is pulled in the distal direction D by the second collar 21. Since the fourth clip
.5 has to be ramped ds a small force is required to release the fourth clip 20.5,
providing the retraction detent.
A fifth clip 2.10 on the chassis 2 abuts a block 20.7 on the first collar 20 prior to use
preventing the first collar 20 and hence the r 7 engaged to the first collar 20 from
moving in the proximal direction P. In orderto release, the fifth clip 2.10 must be
deflected outwards and over the block 20.7. Outward deflection of the fifth clip 2.10 is
lly prevented by the case 12. Once the case 12 has moved on skin contact a
second window 12.8 in the case 12 appears outwardly from the fifth clip 2.10 allowing
outward deflection. The fifth clip 2.10 is then ted by a fourteenth ramp 7.19 on the
carrier 7 when the carrier 7 is pushed in the proximal direction P on button depression
as the fourth clip 20.5 does allow ation of the carrier 7 in the proximal direction P
relative to the first collar 20 but not the other way round. The detent for needle
extension is provided by having to deflect the fifth clip 2.10 when it is loaded by the
control spring 19.
Figures 24A and 248 show longitudinal sections of a third embodiment of the needle
extension control mechanism 24, also arranged to perform the functions of the detent
mechanism 18. Figure 25 is an isometric view of the needle extension control
mechanism 24 of figure 24.The embodiment is similar to that illustrated in figures 22A,
228 and 23. The difference is that the fifth clip 2.10 is ed on the first collar 20 and
the block 20.7 is arranged on the chassis 2, i.e. their position has been switched, so
there are two clips 2.10 and 20.5 on the first collar 20.
The fourth clip 20.5 is identical to that in figure 228. it keeps the first collar 20
connected to the carrier 7 until the needle retraction is triggered, ensuring full needle
extension length or depth is reached and maintained until the retraction cycle is initiated
by displacing the case backwards in distal ion relative to the chassis, eg. when
removing the njector 1 from the skin.
The fifth clip 2.10 provides the detent for needle extension and releases the first collar
from the chassis 2, ting needle extension. The fifth clip 2.1 O prevents the first
collar 20 and hence the carrier 7 engaged to the first collar 20 from moving in the
proximal direction P priorto use by abutting the block 20.7 on the chassis 2. In order to
e, the fifth clip 2.10 must be deflected outwards and overthe block 20.7. Outward
deflection of the fifth clip 2.10 is initially prevented by the case 12. Once the case 12
has moved on skin contact the second window 12.8 in the case 12 appears outwardly
from the fifth clip 2.10 allowing outward deflection. The fifth clip 2.10 is then deflected by
the fourteenth ramp 7.19 on the carrier 7 when the carrier 7 is pushed in the proximal
direction P on button depression as the fourth clip 20.5 does allow translation of the
carrier 7 in the proximal direction P ve to the first collar 20 but not the other way
round. The detent for needle extension is provided by having to deflect the fifth clip 2.10
when it is loaded by the control spring 19.
Figures 26A and 268 show a udinal section of a third ment of the feedback
release mechanism 31. This embodiment works without the need for a dedicated
feedback spring. The plunger 9 comprises a proximally ramped rib 9.2 arranged to splay
two seventh clips 7.21 on the carrier 7 immediately prior to the end of dose. When the
proximally ramped rib 9.2 has travelled past the seventh clips 7.21 they snap back and
impact the plunger 9 ting a sound. The tubular shape of the carrier 7 helps to
transmit the sound. Figure 26A shows the ck release mechanism 31 before
release. Figure 268 shows the feedback release mechanism 31 after release. Proximal
faces of the h clips 7.21 on the r 7 are y offset to facilitate assembly by
lifting the seventh clips 7.21 over the distal side of the proximally ramped rib 9.2 one by
one.
Figures 27A and 278 show longitudinal ns of another embodiment of the auto—
injector 1 in different section planes, the ent section planes approximately 90°
rotated to each other, wherein the auto-injector 1 is in an initial state prior to use. The
auto—injector 1 is essentially identical to the one described in figures 1 to 16. However,
other than the auto—injector of figures 1 to 16 the auto-injector1 of this embodiment has
a wrap-over sleeve trigger instead of a trigger button.
The wrap-over sleeve trigger 12 is the same component as the case 12 which has a
closed distal end face 12.10 other than the one in figures 1 to 16. An internal trigger
button 13 is arranged at the distal end inside the sleeve trigger 12. Otherthan in figures
1 to 16 the trigger button 13 is not visible nor does it protrude from the case 12 in any
state. In the initial state a clearance 33 is provided between the distal end face 12.10 of
the sleeve trigger 12 and the internal trigger button 13 allowing for some travel of the
sleeve trigger 12 without interfering with the trigger button 13.
As the auto-injector1 does not differfrom the auto—injector of figures 1 to 16 in other
ts it is essentially operated in the same way with the following exceptions:
As the chassis 2 is placed against the injection site the sleeve r 12 translates in
the proximal ion P relative to the chassis 2 into the advanced position in a first
phase of sleeve travel removing the clearance 33 between the distal end face 12.10 of
the sleeve trigger 12 and the internal trigger button 13. As in the embodiment of figures
1 to 16 this motion unlocks the detent mechanism 18 and the trigger button 13. As the
user continues to depress the sleeve trigger 12 in a second phase of sleeve travel
3O y further ing it in the proximal direction P the distal end face 12.10 hits the
ai trigger button 13 thereby depressing it until the first coliar 20 is released from
the chassis 2 and the control spring force is coupled on to the carrier 7. The carrier 7
then advances until the internal trigger button 13 stops on another rib in the case 12 and
the plunger release mechanism 27 is released (note the peg 14 is shorter in this
embodiment.
From a user perspective, the detent mechanism 18 is arranged to provide a resistive
force when the user reaches the second phase of sleeve travel. internally, there is no
difference to the embodiment of figures 1 to 16 at this point.
Needle extension is triggered by the user fully advancing the sleeve trigger 12 in the
1O second phase of sleeve travel thereby fully sing the internai trigger button 13 and
overcoming the detent mechanism as in the embodiment of figures 1 to 16.
As the control spring 19 takes over on button depression fully advancing the carrier 7 for
needle extension the internal trigger button 13 s out on an internal fifth rib 12.11
in the sleeve trigger 12 and the internal trigger button 13 switches back to being locked
to the sleeve trigger 12 as in figure 160.
The embodiment of figures 27A and 278 may also be combined with the alternative
features illustrated in figures 17 to 26.
It goes without saying that in all ramped engagements between two components
bed in the above embodiments there may be just one ramp on one or the other
ent or there may be ramps on both components t icantly influencing
the effect of the ramped engagement.
List of References
1 auto-injector
2 chassis
2.1 resilient beam
2.2 first beam head
2.3 proximal third ramp
1O 2.4 distal h ramp
2.5 aperture
2.6 third clip
2.7 slot
2.8 fourth beam head
2.9 third rib
2.10 fifth ciip
2.11 sixth clip
3 synnge
4 hollow injection needle
5 protective needle sheath
6 stopper
7 carrier
7.1 ramp member
7.2 proximal fourth ramp
7.3 distal fifth ramp
7.4 carrier detent
7.5 second recess
7.6 distal tenth ramp
7.7 third recess
7.8 twelfth ramp
7.9 longitudinal aperture
7.10 second rib
7.11 first window
7.12 first clip
7.13 second clip
7.14 first section
7.15 second n
7.16 third beam head
7.17 fifth recess
7.18 fourth rib
7.19 fourteenth ramp
1O 7.20 fifteenth ramp
7.21 seventh clips
drive spring
plunger
9.1 ramp member
9.2 proximaliy ramped rib
carrier end face
11 thrust face
12 case
12.1 first case detent
12.2 second case detent
12.3 first rib
12.4 first back stop
12.5 fourth recess
12.6 ramp feature
12.7 sixth recess
12.8 second window
12.9 third window
12.10 distal end face
12.11 fifth rib
13 trigger button
13.1 proximal beam
13.2 outward first ramp
13.3 inward second ramp
13.4 ramped outward boss
13.5 inward protrusion
13.6 second back stop
14 peg
resilient arm
16 first recess
17 distal plunger sleeve
18 detent ism
1O 19 control spring
first collar
.1 arrowhead
.2 outward sixth ramp
.3 inward ninth ramp
20.4 tab
.5 fourth clip
.6 inward proximal thirteenth ramp
.7 block
.8 fifth clip
21 second collar
21.1 proximal beam
21.2 second beam head
21.3 inward boss
21.4 distal outward eighth ramp
21.5 longitudinal rib
22 cap
22.1 inner sleeve
23 barb
24 needle extension control ism
25 syringe retraction control mechanism
26 button release mechanism
27 plunger release mechanism
28 feedback component
28.1 elongate portion
28.2 distal end plate
28.3 outward eleventh ramp
29 feedback spring
second resilient arm
.1 ramped inward boss
31 feedback release mechanism
32 tor window
’10 33 clearance
distal end, distal direction
inward direction
medicament
TOE outward direction
al end, proximal direction
Claims (18)
1. Auto-injector for administering a dose of a liquid medicament. comprising: — a tubular chassis telescopable in a r case, — a carrier subassembly comprising a tubular r slidably arranged relative to the chassis inside the case, the carrier adapted to contain a syringe with a hollow injection needle, a drive spring and a plunger for forwarding load of the drive spring to a stopper of the syringe, wherein the syringe is lockable for joint axial translation with the carrier, - a trigger button arranged distally or laterally in or on the case, - a control spring arranged around the carrier, 10 - a needle extension control mechanism for coupling a proximal end of the control spring to either the carrier for advancing it for needle extension or to the s for needle retraction ing on the relative axial position of the carrier and the chassis. - a plunger release mechanism arranged for releasing the plunger for expelling the medicament when the carrier has at least almost reached an extended proximal position, 15 - a detent mechanism arranged for coupling the chassis to the r for joint axial translation relative to the case, wherein the detent mechanism is arranged to decouple the s from the carrier upon actuation of the r button thus allowing the carrier to move relative to the chassis so as to cause the needle extension control ism to switch the proximal end of the control spring to the r for needle extension, 20 - a syringe retraction control mechanism arranged for coupling a distal end of the control spring to either the carrier for needle retraction or to the case othenivise.
2. Auto—injector according to claim 1, characterized in that the needle extension control mechanism comprises a first collar biased by the control spring in a proximal direction, wherein at least one resilient beam is proximally ed on the first collar, 25 wherein respective es are arranged in the carrier and case, wherein a ersal extension of a head of the resilient beam is wider than a gap between the carrier and the chassis causing the head of the resilient beam to abut a distal face on the recess in the chassis while being prevented from deflecting in an inward direction by the carrier or to abut a distal face on the recess in the carrier while being prevented from deflecting in an 30 outward direction by the chassis thereby fonlvarding load from the control spring to the r for needle ion. wherein the resilient beam is arranged to be switched between the s and the r by ramped engagement of the head to the distal faces under load of the control spring depending on the ve longitudinal position between the chassis and the carrier.
3. Auto-injector according to claim 1 or 2, characterized in that the plunger release mechanism comprises at least one resiiient arm on the carrier arranged to be in a ramped engagement to the plunger so as to age them under load of the drive spring, wherein a peg protrudes from a distal end face of the trigger button in the proximal direction in a manner to support the resilient arm preventing disengagement of the carrier from the plunger and thus release of the drive spring when the carrier is in a distal position, wherein the r button is arranged to remain in position ve to the 10 case when the carrier is translated for advancing the needle so as to pull the resilient arm away from the peg thus allowing deflection of the ent arm due to the ramped engagement under load of the drive spring for disengaging the plunger from the r and releasing the drive spring for movement of the plunger when the carrier has reached a predefined position relative to the case. 15
4. Auto-injector according to any one of the preceding claims, characterized in that the detent mechanism is arranged to e a resistive force which has to be overcome to advance the carrier in the proximal direction for needle extension.
5. Auto-injector according to any one of the preceding claims, characterized in that the detent mechanism is arranged to provide a resistive force resisting translation of the 20 carrier in the distal direction relative to the chassis for keeping the carrier in a defined position in a transitional state with both ends of the control spring decoupled from the carrier.
6. njector according to claim 4 or 5. characterized in that the detent mechanism comprises a resilient beam on the chassis and a id ramp member on 25 the r, the resilient beam being essentially straight when relaxed and having a first beam head arranged to interact in a ramped engagement with a al fourth ramp or a distal fifth ramp on the rhomboid ramp member in such a manner that application of a translative force on the carrier relative to the chassis in the proximal direction with the first beam head engaged to the fourth ramp deflects the resilient beam in one transversal 30 direction when a predetermined value of the translative force, at least depending on the resilience of the resilient beam, is overcome so as to allow the first beam head to travel along one transversal side of the rhomboid ramp member on continued relative translation of the components, n the resilient beam is allowed to relax when the first beam head has reached the fifth ramp thereby engaging it in a manner that application of a translative force on the carrier in the distal direction deflects the resilient beam in the other transversal direction when a predetermined value of the translative force, at least depending on the resilience of the resilient beam, is overcome so as to allow the first beam head to travel along the other transversal side of the rhomboid ramp member on continued translation of the carrier.
7. Auto-injector ing to any one of the preceding Claims, characterized in that 10 the case is arranged to lock the detent mechanism prior to being translated in the ai direction relative to the chassis when the chassis is being pressed against an injection site, wherein the case when translated into an advanced position in the proximal direction is ed to unlock the detent mechanism rendering it operable.
8. Auto-injector according to any one of the preceding claims, characterized in that 15 the ly arranged trigger button is at least initially d to the carrier, wherein the case is arranged to abut the trigger button in the initial state preventing depression of the trigger button, n on translation of the case into the advanced position when the chassis is being pressed against the injection site the trigger button remains coupled to the carrier thus emerging from the case so as to allow depression for starting an injection 20 cycle.
9. Auto-injector according to any one of the ing claims, characterized in that the syringe retraction control mechanism comprises a second collar bearing against the distal end of the control spring and having a resilient proximal beam with a second beam head having an inward boss, wherein the second beam head is arranged to be in a 25 ramped engagement with a second case detent in the case in a manner ramping the second beam head in the inward direction under load of the control spring in the distal direction, wherein the inward boss is arranged to inwardly abut the carrier for preventing inward deflection of the second beam head and keep the second coliar locked to the case, wherein a third recess is ed in the carrier for ng the inward boss to be 30 ly deflected on translation of the case in the distal ion relative to the carrier on removal of the auto-injector from the injection site.
10. Auto—injector ing to any one of the preceding claims, characterized in that the trigger button is arranged distally, wherein the case is arranged as a wrap-over sleeve trigger having a closed distal end face covering the trigger button, wherein in an initial state a clearance is provided between the distal end face of the sleeve trigger and the trigger button allowing for some travel of the sleeve trigger against the bias of the control spring in the proximal direction in a first phase before abutting the trigger button.
11. Auto-injector according to any one of the preceding claims, characterized in that a releasable feedback component is provided, capable of, upon release, generating an audible and/or tactile feedback to a user, n the feedback component is arranged to 10 be released when the plunger reaches a position relative to the syringe in which the stopper is located in proximity of a proximal end of the syringe, and n the released feedback component impacts on a housing component indicating the end of the injection.
12. Auto—injector according to any one of the claims 2 to 11, characterized in that a visual use indicator is provided, comprising at least one indicator window in the case, 15 wherein a part of the chassis is arranged to be located behind the indicator window when the case is in its distal position biased by the control , wherein a tab on the first collar is located outwardly from the part of the chassis after the collar has been translated in the proximal direction during needie extension, wherein the tab and the part of the chassis exhibit a visually distinctive feature. 20
13. Method of operating an auto—injector, the auto—injector comprising: - a tubular s opable in a r case, ~ a r subassembly comprising a tubular carrier slidably arranged relative to the s inside the case, the r adapted to contain a syringe with a hollow ion needle, a drive spring and a plunger for forwarding load of the drive spring to a stopper of 25 the syringe, wherein the syringe is lockable for joint axial translation with the carrier, - a trigger button arranged distally or laterally in or on the case, - a control spring arranged around the carrier, - a needle ion control mechanism for coupling a proximal end of the control spring to either the carrier or to the chassis, 30 - a plunger e mechanism arranged for locking the drive spring, - a detent mechanism arranged for ng the chassis to the carrier, ~ a syringe tion control mechanism arranged for coupling a distal end of the control spring to either the carrier or to the case, the method comprising the steps of: — coupling the proximal end of the control spring to the carrier by the needle extension control mechanism, preventing release of the drive spring by the plunger release mechanism, preventing decoupling of the chassis from the carrier by the detent mechanism and coupling the distal end of the control spring to the case by the syringe retraction control mechanism in an initial state, - ating the case in the proximal direction relative to the chassis t the force of the control spring 1O ~ unlocking the detent mechanism when the case is translated into an advanced position y allowing translation of the carrier relative to the chassis - translating the carrier in the proximal direction thereby switching the needle extension control mechanism so as to decouple the proximal end of the control spring from the chassis and couple it to the carrier, thereby releasing the control spring for ing the 15 carrier for needle extension, - releasing the drive spring by the plunger release mechanism when the needle at least almost reaches an extended proximal position thereby allowing the drive spring to advance the plunger and the stopper for at least partially expeliing the medicament. - ating the case in the distai direction under load of the control spring relative to the 20 carrier - decoupiing the al end of the control spring from the carrier and coupling it to the s by the needle extension l mechanism and decoupling the distal end of the control spring from the case and coupling it to the carrier by the syringe retraction control mechanism when the case reaches a defined position relative to the carrier during 25 translation in the distal direction, - retracting the carrier subassembly into the s into a needle safe position under load of the control .
14. Method according to claim 13, characterized in that a resistive force is provided by the detent mechanism which has to be overcome to advance the carrier in the 30 proximal direction for needle extension.
15. Method according to claim 13 or 14, characterized in that a resistive force is provided by the detent mechanism resisting ation of the carrier in the distal direction relative to the chassis for keeping the r in a defined on after decoupling the proximal end of the controi spring from the carrier and coupling it to the chassis by the needle extension control mechanism and before decoupling the distal end of the control spring from the case and coupling it to the carrier by the syringe retraction controi mechanism.
16. Method according to any one of claims 13 to 15, wherein the auto—injector is the auto-injector ing to any one of the claims 1 to 12.
17. njector for administering a dose of a liquid medicament, the auto-injector substantially as herein described with reference to any embodiment shown in the accompanying drawings; 1O
18. Method of operating an auto-injector, the method ntially as herein described with reference to any embodiment shown in the accompanying drawings.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11155032.3 | 2011-02-18 | ||
EP11155032A EP2489381A1 (en) | 2011-02-18 | 2011-02-18 | Auto-injector |
US201161445610P | 2011-02-23 | 2011-02-23 | |
US61/445,610 | 2011-02-23 | ||
PCT/EP2012/052640 WO2012110573A1 (en) | 2011-02-18 | 2012-02-16 | Auto-injector |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ614081A NZ614081A (en) | 2014-11-28 |
NZ614081B2 true NZ614081B2 (en) | 2015-03-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11819670B2 (en) | Auto-injector | |
US11484655B2 (en) | Auto-injector | |
US10556064B2 (en) | Auto-injector | |
US20190358405A1 (en) | Auto-Injector | |
AU2012217080B2 (en) | Auto-injector | |
AU2012217087B2 (en) | Auto-injector | |
AU2012217084A1 (en) | Auto-injector | |
NZ614081B2 (en) | Auto-injector | |
NZ614086B2 (en) | Auto-injector | |
NZ614211B2 (en) | Auto-injector | |
NZ614216B2 (en) | Auto-injector | |
NZ614084B2 (en) | Auto-injector | |
NZ614084A (en) | Auto-injector |